BAX and prostate cancer: SALL4 overexpression in MDS and AML cells results in an increase in Bcl-2 expression and cell survival [75], whereas SALL4 knockdown markedly inhibits Bcl-2 expression in prostate cancer [76], breast cancer [16,77], colorectal cancer (CRC) [78], and nasopharyngeal carcinoma (NPC) [79], and it induces the expression of pro-apoptotic Bax in prostate cancer [76] and NPC [79].